Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5151-5158

  Zhang, Jingli ^a   Qiu, Shuo ^a,b   Zhang, Yujian ^a,c   Merino, Maria ^a   Fetsch, Patricia ^a   Avital, Itzhak ^a   Filie, Armando ^a   Pastan, Ira ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DICKINSON COLLEGE   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Mesothelin; MPF; Peritoneal mesothelioma; Pleural mesothelioma; SS1P

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOTOXIN SS1P; MESOTHELIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CANCER GROWTH; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PERITONEUM MESOTHELIOMA; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ASCITES; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84872542438     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Robinson BWS and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
2. Hassan R and Alexander R: Non-pleural mesotheliomas: mesothelioma of the peritoneum, tumica vaginalis and pericardium. Hematol Oncol Clin North Am 19: 1067-1087, 2005.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
4. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE and Alexander HR: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21: 4560-4567, 2003.
5. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P and Sugarbaker PH: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27: 6237-6242, 2009.
6. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004.
7. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996.
8. Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381, 1992.
9. Ordóñez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197, 2003.
10. Hassan R, Kreitman RJ, Pastan I and Willingham MC: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13: 243-247, 2005.
11. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE and Hruban RH: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas. Clin Cancer Res 27: 3862-3868, 2001.
12. Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27: 1418-1428, 2003.
13. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M and Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198, 2004.
14. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee, B, Pastan I and Patankar MS: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5: 50-65, 2006.
15. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N and Ochi N: A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 269: 805-808, 1994.
16. Wang T, Kajino K, Abe M, Tan K, Maruo M, Sun G, Hagiwara Y, Maeda M and Hino O: Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. Int J Mol Med 26: 185-191, 2010.
17. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE and Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.
18. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I and Onda M: Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12: 447-453, 2006.
19. Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I and Naka T: Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 62: 45-54, 2008.
20. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR and van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181: 620-625, 2010.
21. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL and Lee YC: Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 180: 437-444, 2009.
22. Hassan R and Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53, 2008.
23. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham M and Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus intravenous infusion to patients with mesothelin expressing mesotheliomas, ovarian and pancreatic cancer. Clin Cancer Res 13: 5144-5149, 2007.
24. Hassan R, Sharon E, Schuler B, Mallory Y, Zhang J, Ling A and Pastan I: Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. J Clin Oncol 29(suppl): abstract 7026, 2011.
25. Lottner C, Schwarz, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F and Brockhoff G: Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 205: 577-584, 2005.
26. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH and Pastan I: Phase II trial of recombinant immunotoxin RFB(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27: 2983-2990, 2009.
27. Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I and Fidler IJ: Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17: 643-651, 2000.
28. Chang PK, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I and Willingham MC: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16: 259-268, 1992.